Table 1.
Demographics and control-trial results
| Subject | Age/ sex | Dual AV-nodal pathways? | Antiarrhythmic medications | Heart disease | Electrophysiology study indication | Pre/post autonomic blockade | Control successes/ attempts | Different nominal VAs | σ̄p, ms | σ̄c, ms | Δσ, % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 38/F | Yes | None | WPW | Palpitations, presyncope | Post | 14/14 | 9 | 17.3 | 6.1 | 65 |
| 2 | 35/F | No | None | WPW | SVT | Pre | 8/8 | 4 | 14.1 | 9.0 | 36 |
| 2 | 35/F | No | None | WPW | SVT | Post | 8/8 | 4 | 12.0 | 3.9 | 68 |
| 3 | 62/M | Yes | Digoxin, disopyramide | — | SVT | Pre | 2/2 | 2 | 43.8 | 28.5 | 35 |
| 3 | 62/M | Yes | Digoxin, disopyramide | — | SVT | Post | 2/2 | 1 | 5.4 | 3.1 | 43 |
| 4 | 75/M | No | Digoxin, verapamil | CAD, HTN | SVT | Pre | 10/10 | 3 | 9.7 | 4.3 | 56 |
| 5 | 51/M | No | Digoxin | IDCM | SVT | Post | 8/10 | 1 | 9.1 | 5.0 | 45 |
σ̄p, σ̄c, and Δσ are defined in Results. WPW, Wolf–Parkinson–White syndrome; CAD, coronary artery disease; HTN, hypertension; IDCM, idiopathic dilated cardiomyopathy; SVT, supraventricular tachycardia.